StreetInsider.com News Articles

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Thu, 01 Oct 2026 08:00:00 -0400

New data will represent one of the first large-scale real-world effectiveness analyses of VTAMA cream in patients with atopic dermatitis (AD)

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that a new real-world analysis of patients with atopic dermatitis (AD) treated with VTAMA® (tapinarof) cream, 1% will be on display at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

The analysis, entitled Real World Effectiveness of Tapinarof 1% Cream for Atopic Dermatitis, evaluates VTAMA’s effectiveness in real-world

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Thu, 01 Oct 2026 08:00:00 -0400

New data will represent one of the first large-scale real-world effectiveness analyses of VTAMA cream in patients with atopic dermatitis (AD)

The analysis, entitled Real World Effectiveness of Tapinarof 1% Cream for Atopic Dermatitis, evaluates VTAMA’s effectiveness in real-world

FDA accepts review of application to extend Miudella IUD use to 6 years

Mon, 14 Sep 2026 07:30:27 -0400

Organon (NYSE: OGN) announced that the U.S. Food and Drug Administration has accepted for review a supplemental New Drug Application filed by Sebela Women's Health seeking to extend the approved duration of use for Miudella, a hormone-free copper intrauterine device, from three to six years.

The FDA's PDUFA action date is expected in the second quarter of calendar year 2027. Miudella is currently indicated for the prevention of pregnancy in females of reproductive potential for up to three years and is anticipated to become commercially available in late 2026.

Organon completed an exclusive global licensing agreement with Sebela for Miudella in June

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

Mon, 14 Sep 2026 07:30:00 -0400

Sebela’s sNDA Seeks to Extend Approved Duration of Use from 3 to 6 Years

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the US Food and Drug Administration (FDA) has accepted for review Sebela Women’s Health’s supplemental New Drug Application (sNDA) for MIUDELLA® (copper intrauterine system) for an extended duration of use for up to 6 years with Prescription Drug User Fee Act (PDUFA) action expected in the second quarter of calendar year 2027.

In June of 2026, Organon

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

Mon, 14 Sep 2026 07:30:00 -0400

Sebela’s sNDA Seeks to Extend Approved Duration of Use from 3 to 6 Years

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the US Food and Drug Administration (FDA) has accepted for review Sebela Women’s Health’s supplemental New Drug Application (sNDA) for MIUDELLA® (copper intrauterine system) for an extended duration of use for up to 6 years with Prescription Drug User Fee Act (PDUFA) action expected in the second quarter of calendar year 2027.

In June of 2026, Organon

Orogen Royalties acquires undrilled Nevada gold project

Thu, 10 Sep 2026 07:31:17 -0400

Orogen Royalties Inc. (TSXV: OGN)(OTCQX: OGNNF) has acquired the Serpent gold project in central Nevada, according to a press release from the Vancouver-based company.

The project covers 225 Bureau of Land Management claims across approximately 18.8 square kilometers, located 25 kilometers northwest of Rachel, Nevada. It was generated in partnership with Altius Minerals Corporation and is available for option or sale.

The Serpent project is described as a low-sulphidation epithermal gold target focused on a series of gold-bearing structures within an eight-kilometer trend of alteration. Reconnaissance rock sampling has returned gold values of up to 0.95 grams per tonne in the primary

Orogen Royalties Acquires the Serpent Gold Project in Nevada

Thu, 10 Sep 2026 07:30:00 -0400

VANCOUVER, BC / ACCESS Newswire / September 10, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the acquisition of the Serpent gold project in Nevada, USA.

Project Highlights

Serpent is a district scale, low-sulphidation epithermal gold target located in central Nevada
Focused on a series of gold-bearing structures within an eight-kilometre trend of alteration
Highly anomalous gold in rocks (up to 0.95 grams per tonne ("g/t") gold) associated with the shallow expression of an epithermal deposit
Underexplored with no evidence of historical drilling
Generated in partnership with Altius Minerals Corporation

The Serpent

Orogen Royalties Acquires the Serpent Gold Project in Nevada

Thu, 10 Sep 2026 07:30:00 -0400

Project Highlights

Serpent is a district scale, low-sulphidation epithermal gold target located in central Nevada
Focused on a series of gold-bearing structures within an eight-kilometre trend of alteration
Highly anomalous gold in rocks (up to 0.95 grams per tonne ("g/t") gold) associated with the shallow expression of an epithermal deposit
Underexplored with no evidence of historical drilling
Generated in partnership with Altius Minerals Corporation

The Serpent

Orogen Royalties acquires two Utah gold projects with Triple Flag

Wed, 02 Sep 2026 08:01:17 -0400

Orogen Royalties Inc. (TSXV: OGN)(OTCQX: OGNNF) has acquired the Toro de Oro and El Gigante gold projects in southwest Utah, according to a company statement. Both projects were generated in partnership with Triple Flag Precious Metals and are available for option or sale.

Toro de Oro covers approximately 8.6 square kilometers of Bureau of Land Management claims and Utah State mineral leases located 30 kilometers northeast of Modena, Utah. The project is situated in the Indian Peak Caldera Complex and is characterized by advanced argillic alteration and chalcedony vein sets. The company describes the geology as similar to AngloGold Ashanti's Arthur

Orogen Royalties Acquires Two Gold Projects in Southwest Utah

Wed, 02 Sep 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / September 2, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El Gigante gold projects in Southwest Utah, USA.

Project Highlights

Two low-sulphidation epithermal targets located in caldera complexes of southwest Utah
Toro de Oro is centered on an extensive footprint of steam cap alteration and chalcedonic vein sets indicating the high-level expression of an epithermal system, geologically similar to AngloGold Ashanti's Arthur Project
El Gigante contains two separate quartz veins up to and exceeding three

Orogen Royalties Acquires Two Gold Projects in Southwest Utah

Wed, 02 Sep 2026 08:00:00 -0400

Project Highlights

Two low-sulphidation epithermal targets located in caldera complexes of southwest Utah
Toro de Oro is centered on an extensive footprint of steam cap alteration and chalcedonic vein sets indicating the high-level expression of an epithermal system, geologically similar to AngloGold Ashanti's Arthur Project
El Gigante contains two separate quartz veins up to and exceeding three

National Can-RISE Study to Help Close Critical Gaps in Menopause Research